Bexitrol F MDPI 50 mcg+250 mcg is a fixed-dose combination inhalation therapy containing Salmeterol, a long-acting beta-2 adrenergic agonist, and Fluticasone Propionate, a potent inhaled corticosteroid. It is formulated as a metered dose powder inhaler (MDPI) for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

This combination works by providing sustained bronchodilation while simultaneously controlling airway inflammation, addressing the two key components of chronic respiratory diseases. Bexitrol F MDPI is intended for regular use and helps reduce symptoms, improve lung function, and prevent disease exacerbations. It is not suitable for immediate relief of acute asthma attacks.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Long-acting beta-2 agonist (LABA) + Inhaled corticosteroid (ICS)

Indications

Bexitrol F MDPI 50 mcg+250 mcg is indicated for:

• Maintenance treatment of bronchial asthma in patients not adequately controlled on inhaled corticosteroids alone

• Long-term management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

• Prevention of recurrent asthma symptoms such as wheezing, breathlessness, chest tightness, and nocturnal symptoms

This strength is particularly suitable for patients with moderate persistent asthma or COPD who require combination therapy for optimal control.

Pharmacology

Salmeterol produces prolonged bronchodilation by selectively stimulating beta-2 adrenergic receptors in bronchial smooth muscle. Its long duration of action helps maintain open airways for up to 12 hours, reducing daytime and nighttime respiratory symptoms.

Fluticasone Propionate exerts strong anti-inflammatory effects by inhibiting inflammatory mediators, reducing airway edema, and suppressing inflammatory cell activity. Regular use decreases airway hyper-responsiveness and lowers the risk of asthma exacerbations.

The synergistic action of these two agents provides improved symptom control and better disease management compared to monotherapy.

Dosage and Administration

Bexitrol F MDPI is for inhalation use only.

• The usual recommended dose is one inhalation twice daily or as directed by a physician

• The inhaler should be used regularly at the same times each day

• Rinse the mouth with water after each use and spit out to reduce the risk of oral fungal infections

Patients should be instructed on correct inhaler technique to ensure maximum benefit.

Contraindications

Bexitrol F MDPI is contraindicated in:

• Patients with known hypersensitivity to Salmeterol, Fluticasone Propionate, or any excipient

• Acute episodes of asthma or severe bronchospasm requiring rapid-acting bronchodilators

Side Effects

Possible side effects include:

• Throat irritation or hoarseness

• Headache

• Cough

• Oral candidiasis

• Tremor or palpitations (uncommon)

Most adverse effects are mild and reversible with proper use.

Precautions and Warnings

• Not intended for acute symptom relief

• Use cautiously in patients with cardiovascular disease, diabetes mellitus, or thyroid disorders

• Avoid abrupt discontinuation without medical advice

• Long-term use requires periodic medical evaluation

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Pregnancy and Lactation

Use during pregnancy and lactation only if the expected benefit outweighs potential risks, and only under medical supervision.

Storage Conditions

Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children.

Conclusion

Bexitrol F MDPI 50 mcg+250 mcg is an effective maintenance inhaler that combines long-acting bronchodilation with potent anti-inflammatory action. Regular use helps control asthma and COPD symptoms, reduces exacerbations, and supports improved respiratory function and quality of life.